The global molecular cytogenetics market size reached US$ 2.7 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 6.0 Billion by 2032, exhibiting a growth rate (CAGR) of 9.28% during 2023-2032.
Molecular cytogenetics refers to the biomedical research of deoxyribonucleic acid (DNA) mechanisms to investigate genetic mutations and disorders. It studies the structural and functional organization of the chromosomes and their nucleus, genomic variations, expression, evolution and abnormalities, especially in medicinal and cancer-related genetics.
Techniques such as DNA amplification, DNA isolation, gene screens, virtual karyotyping and fluorescence in situ hybridization (FISH) are commonly used for molecular cytogenetics by using DNA probes to visualize and label the genome or its targeted regions. These techniques are highly beneficial in the diagnosis and treatment of various malignant tumors and hematological malignancies.
The increasing prevalence of cancer and other genetic disorders, along with the rising geriatric population, is one of the key factors driving the growth of the market. Molecular cytogenetics is primarily being used for developing predictive models of disease traits and effective treatment strategies. Furthermore, the widespread adoption of targeted therapies for cancer treatment is also augmenting the market growth. FISH and Comparative Genomic Hybridization (CGH) are also used for pharmacogenomic biomarker studies to analyze cancer progression stages and provide personalized treatment to the patient.
Additionally, various technological advancements, such as the development of improved consumables, reagents, software and kits, are acting as other growth-inducing factors. These advancements aid in generating duplicatable, accurate and reliable clinical-pathological test results. Other factors, including significant improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of biomedical sciences, are anticipated to drive the market further.
2. What is the expected growth rate of the global molecular cytogenetics market during 2024-2032?
3. What has been the impact of COVID-19 on the global molecular cytogenetics market?
4. What are the key factors driving the global molecular cytogenetics market?
5. What is the breakup of the global molecular cytogenetics market based on the product type?
6. What is the breakup of the global molecular cytogenetics market based on the technology?
7. What is the breakup of the global molecular cytogenetics market based on application?
8. What is the breakup of the global molecular cytogenetics market based on the end user?
9. What are the key regions in the global molecular cytogenetics market?
10. Who are the key players/companies in the global molecular cytogenetics market?
Molecular cytogenetics refers to the biomedical research of deoxyribonucleic acid (DNA) mechanisms to investigate genetic mutations and disorders. It studies the structural and functional organization of the chromosomes and their nucleus, genomic variations, expression, evolution and abnormalities, especially in medicinal and cancer-related genetics.
Techniques such as DNA amplification, DNA isolation, gene screens, virtual karyotyping and fluorescence in situ hybridization (FISH) are commonly used for molecular cytogenetics by using DNA probes to visualize and label the genome or its targeted regions. These techniques are highly beneficial in the diagnosis and treatment of various malignant tumors and hematological malignancies.
The increasing prevalence of cancer and other genetic disorders, along with the rising geriatric population, is one of the key factors driving the growth of the market. Molecular cytogenetics is primarily being used for developing predictive models of disease traits and effective treatment strategies. Furthermore, the widespread adoption of targeted therapies for cancer treatment is also augmenting the market growth. FISH and Comparative Genomic Hybridization (CGH) are also used for pharmacogenomic biomarker studies to analyze cancer progression stages and provide personalized treatment to the patient.
Additionally, various technological advancements, such as the development of improved consumables, reagents, software and kits, are acting as other growth-inducing factors. These advancements aid in generating duplicatable, accurate and reliable clinical-pathological test results. Other factors, including significant improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of biomedical sciences, are anticipated to drive the market further.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global molecular cytogenetics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, technology, application and end user.Breakup by Product Type:
- Instruments
- Consumables
- Software and Services
- Others
Breakup by Technology:
- Comparative Genomic Hybridization
- Fluorescence in SITU Hybridization (FISH)
- Immunohistochemistry
- Karyotyping
- Others
Breakup by Application:
- Genetic Disorders
- Oncology
- Personalized Medicine
- Others
Breakup by End User:
- Clinical and Research Laboratories
- Hospitals and Pathology Laboratories
- Pharmaceutical and Biotechnology Companies
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging Inc., Biological Industries, Bio-RAD Laboratories Inc., BioView Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Illumina Inc., Oxford Gene Technology, Perkinelmer Inc. and Quest Diagnostics Incorporated.Key Questions Answered in This Report
1. What was the size of the global molecular cytogenetics market in 2023?2. What is the expected growth rate of the global molecular cytogenetics market during 2024-2032?
3. What has been the impact of COVID-19 on the global molecular cytogenetics market?
4. What are the key factors driving the global molecular cytogenetics market?
5. What is the breakup of the global molecular cytogenetics market based on the product type?
6. What is the breakup of the global molecular cytogenetics market based on the technology?
7. What is the breakup of the global molecular cytogenetics market based on application?
8. What is the breakup of the global molecular cytogenetics market based on the end user?
9. What are the key regions in the global molecular cytogenetics market?
10. Who are the key players/companies in the global molecular cytogenetics market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Molecular Cytogenetics Market
6 Market Breakup by Product Type
7 Market Breakup by Technology
8 Market Breakup by Application
9 Market Breakup by End User
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Agilent Technologies Inc.
- Applied Spectral Imaging Inc.
- Biological Industries
- Bio-RAD Laboratories Inc.
- BioView Inc.
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Illumina Inc.
- Oxford Gene Technology
- Perkinelmer Inc.
- Quest Diagnostics Incorporated
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 2.7 Billion |
| Forecasted Market Value ( USD | $ 6 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
